Sequella uses viral technology to highlight TB (tuberculosis)
This article was originally published in Clinica
Executive Summary
Biotechnology company Sequella has received a $300,000 grant from the US National Institute of Allergy and Infectious Diseases to help develop its sputum-based, point-of-care device for detecting tuberculosis (TB) and its drug resistant forms.